PBH

The past six months saw several events impacting Prestige Consumer Healthcare's stock price. In May 2026, the company reported Q4 fiscal 2026 revenues that were 5% lower than the prior year and 6.4% lower than the previous quarter, with significant decreases in the North America OTC Eye & Ear Care and International OTC segments, attributed to Clear Eyes supply constraints and issues with the recently acquired Pillar5 facility, causing an 11.3% stock price decline. In June 2026, PBH acquired LaCorium Health International and the Breathe Right brand along with other brands from Foundation Consumer Healthcare for $1.045 billion, expanding its OTC portfolio. Q1 fiscal 2027 results in August 2026 showed earnings per share of $0.98, beating the consensus estimate, and revenue of $265.71 million, exceeding analysts' expectations and representing a 6.5% increase year-over-year. In September 2026, the company announced its SVP of Operations would retire in August 2026. Overall, the stock price decreased by 24.3% over the last 12 months and saw a -9% change in the past month, with the share price at $44.97 as of September 18, 2026, a 29.29% decline from September 22, 2025.